Cocrystal Pharma, Inc.
COCP
Rank in Stocks
#26253
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching... Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Share Price
$1.11
Last synced: 2026-11-09
Market Cap
$21.29M
Change (1 day)
6.25%
Change (1 year)
-2.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cocrystal Pharma, Inc. (COCP)
Category
Healthcare
Operating Margin for Cocrystal Pharma, Inc. (COCP)
Operating Margin as of November 2026 TTM: -3,063.64%
According to Cocrystal Pharma, Inc.'s latest financial reports, its current operating margin (TTM) is -3,063.64%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Cocrystal Pharma, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3,063.64% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -475.97% | -35.46% |
| 2019 | -737.45% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -69,164.10% | 7.34% |
| 2014 | -64,433.33% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -15.34% | -50.26% |
| 2011 | -30.84% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.95% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cocrystal Pharma, Inc.'s operating margin
What is Cocrystal Pharma, Inc.'s operating margin?
Cocrystal Pharma, Inc.'s operating margin is -3,063.64%, as of Nov 2026.
What was Cocrystal Pharma, Inc.'s operating margin in 2025?
In 2025, Cocrystal Pharma, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Cocrystal Pharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Cocrystal Pharma, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-475.97%).
How does Cocrystal Pharma, Inc.'s operating margin compare with similar companies?
Cocrystal Pharma, Inc.'s operating margin (-3,063.64%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.